The herbal preparation STW 5 affects serotonergic pathways in the brain and colon as well as stress parameters in experimental irritable bowel syndrome
Rattachement africain : Égypte. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Exposure to stress has been related to disturbance in 5-hydroxytryptamine (5-HT) signaling in the brain-gut axis and is considered as a major predisposing factor for the development of irritable bowel syndrome (IBS). The present study aimed to investigate the possible involvement of 5-HT and some other stress-related parameters in the effectiveness of STW 5 against stress-induced IBS. METHODS: Rats were subjected to restraint stress (RS) for 1 h/day for 14 consecutive days to induce IBS-like symptoms and were given STW 5 orally at the same time. At the end of the experiment, blood samples were withdrawn, then animals were euthanized and the brain hippocampi, cerebral cortices, as well as colons were isolated for biochemical and histopathological assessments. RESULTS: RS increased the plasma corticotrophin releasing factor (CRF) with concomitant increase in hippocampal and cortical 5-HT levels, as well as mast cell inflammatory mediators, oxidative stress biomarkers, and histopathological inflammatory changes observed in rat colon. It also decreased the colonic content of 5-HT with consequent decrease in fecal pellet output (FPO). Treatment with STW 5 protected against these changes. CONCLUSION: The protective effect of STW 5 against RS-induced IBS is related to its ability to normalize the induced changes in 5-HT in the brain-gut axis and counteract the stress-induced oxidative stress and inflammation.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- The herbal preparation STW 5 affects serotonergic pathways in the brain and colon as well as stress parameters in experimental irritable bowel syndrome
- Date Crossref
- 24/11/2021
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Cairo University Cairo University, Égypte (code pays fourni par la source)Université ou école supérieure
-
EVA Pharma (Egypt) Égypte (code pays fourni par la source)Entreprise
-
National Organization for Drug Control and Research Cairo, Égypte (code pays fourni par la source)Structure de recherche
-
Faculty of Pharmacy Pharmacology and Toxicology Department Cairo University, Égypte (pays nommé en fin d’affiliation)Université ou école supérieure
-
Research and Development Department EVA Pharma Cairo Egypt Cairo, Égypte (pays nommé en fin d’affiliation)Institution
-
Physiology Department Cairo, Égypte (pays nommé en fin d’affiliation)Institution
Cairo University (Cairo University, Égypte), EVA Pharma (Egypt) (Égypte) et National Organization for Drug Control and Research (Cairo, Égypte), avec 3 autres affiliations. Pays d’affiliation : Égypte.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.